ACLARION, INC. Selling and Marketing Expense
ACLARION, INC. (ACON) reported Selling and Marketing Expense of $877.16 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-06
- ACLARION, INC. selling and marketing expense for the quarter ending 2026-06-30 was $877.16K, a 155.16% increase year-over-year.
- ACLARION, INC. selling and marketing expense for the quarter ending 2026-03-31 was $908.80K, a 200.35% increase year-over-year.
- ACLARION, INC. selling and marketing expense for the quarter ending 2025-12-31 was $621.84K, a 84.15% increase year-over-year.
- ACLARION, INC. selling and marketing expense for the quarter ending 2025-09-30 was $632.41K, a 171.68% increase year-over-year.
- ACLARION, INC. selling and marketing expense for fiscal 2025 was $1.90M, a 94.62% increase from fiscal 2024.
- ACLARION, INC. selling and marketing expense for fiscal 2024 was $976.55K, a 29.00% increase from fiscal 2023.
- ACLARION, INC. selling and marketing expense for fiscal 2023 was $757.00K, a 52.01% increase from fiscal 2022.
- ACLARION, INC. selling and marketing expense for fiscal 2022 was $498.00K, a 50.54% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $877.16K 10-Q · filed 2026-08-06 | $1.79M 10-Q · filed 2026-08-06 | $2.41M derived: sum of 3 quarters · filed 2026-08-06 | $3.04M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $908.80K 10-Q · filed 2026-05-13 | $1.53M derived: sum of 2 quarters · filed 2026-05-13 | $2.16M derived: sum of 3 quarters · filed 2026-05-13 | $2.51M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $621.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.25M derived: sum of 2 quarters · filed 2026-03-18 | $1.60M derived: sum of 3 quarters · filed 2026-08-06 | $1.90M 10-K · filed 2026-03-18 | |
| 2025-09-30 | $632.41K 10-Q · filed 2025-11-12 | $976.17K derived: sum of 2 quarters · filed 2026-08-06 | $1.28M 10-Q · filed 2025-11-12 | $1.62M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $343.76K 10-Q · filed 2026-08-06 | $646.35K 10-Q · filed 2026-08-06 | $984.03K derived: sum of 3 quarters · filed 2026-08-06 | $1.22M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $302.58K 10-Q · filed 2026-05-13 | $640.27K derived: sum of 2 quarters · filed 2026-05-13 | $873.04K derived: sum of 3 quarters · filed 2026-05-13 | $1.10M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $337.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $570.46K derived: sum of 2 quarters · filed 2026-03-18 | $795.50K derived: sum of 3 quarters · filed 2026-03-18 | $976.55K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $232.78K 10-Q · filed 2025-11-12 | $457.81K derived: sum of 2 quarters · filed 2025-11-12 | $638.87K 10-Q · filed 2025-11-12 | $817.90K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $225.04K 10-Q · filed 2025-08-14 | $406.09K 10-Q · filed 2025-08-14 | $585.13K derived: sum of 3 quarters · filed 2025-08-14 | $778.02K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $181.06K 10-Q · filed 2025-05-15 | $360.09K derived: sum of 2 quarters · filed 2025-05-15 | $552.99K derived: sum of 3 quarters · filed 2025-05-15 | $760.78K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $179.03K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-09 | $371.93K derived: sum of 2 quarters · filed 2025-04-09 | $579.72K derived: sum of 3 quarters · filed 2025-04-09 | $757.00K 10-K · filed 2025-04-09 | |
| 2023-09-30 | $192.90K 10-Q · filed 2024-11-14 | $400.69K derived: sum of 2 quarters · filed 2024-11-14 | $577.97K 10-Q · filed 2024-11-14 | $722.52K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $207.79K 10-Q · filed 2024-08-14 | $385.07K 10-Q · filed 2024-08-14 | $529.62K derived: sum of 3 quarters · filed 2024-08-14 | $689.01K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $177.28K 10-Q · filed 2024-05-15 | $321.83K derived: sum of 2 quarters · filed 2024-05-15 | $481.22K derived: sum of 3 quarters · filed 2024-05-15 | $605.98K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $144.55K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $303.94K derived: sum of 2 quarters · filed 2024-03-28 | $428.69K derived: sum of 3 quarters · filed 2024-03-28 | $498.00K 10-K · filed 2024-03-28 | $537.07K 10-K · filed 2023-02-27 |
| 2022-09-30 | $159.39K 10-Q · filed 2023-11-14 | $284.15K derived: sum of 2 quarters · filed 2023-11-14 | $353.46K 10-Q · filed 2023-11-14 | $475.06K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $124.76K 10-Q · filed 2023-08-25 | $194.07K 10-Q · filed 2023-08-25 | $315.68K derived: sum of 3 quarters · filed 2023-08-25 | $394.05K derived: sum of 4 quarters · filed 2023-08-25 | |
| 2022-03-31 | $69.31K 10-Q · filed 2023-07-03 | $190.92K derived: sum of 2 quarters · filed 2023-07-03 | $269.29K derived: sum of 3 quarters · filed 2023-07-03 | $334.25K derived: sum of 4 quarters · filed 2023-07-03 | |
| 2021-12-31 | $121.61K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-12 | $199.99K derived: sum of 2 quarters · filed 2023-06-12 | $264.95K derived: sum of 3 quarters · filed 2023-06-12 | $330.81K 10-K/A · filed 2023-06-12 | |
| 2021-09-30 | $78.38K 10-Q · filed 2022-11-14 | $143.34K derived: sum of 2 quarters · filed 2022-11-14 | $209.21K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $64.96K 10-Q · filed 2022-08-15 | $130.83K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $65.87K 10-Q · filed 2022-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |